Profile data is unavailable for this security.
About the company
Turk Ilac ve Serum Sanayi AS is a Turkey-based pharmaceutical company. The main activity of the Company is to manufacture and sell all kinds of tablets, capsules, ampoules, vials, ointments-creams, intravenous serums, parenteral solutions, nutritional solutions, amino acids and other chemical substances. The company also acts as the representative or sales agency of other domestic and foreign pharmaceutical companies, as well as importing and marketing veterinary, cosmetics and pesticides. Turk Ilac manufactures in accordance with Current Good Manufacturing (GMP) and Good Laboratory Practice (GLP) principles with its approximately 300 employees in its facilities on a total area of 56.000 square meters in the Ankara - Akyurt region.
- Revenue in TRY (TTM)3.47bn
- Net income in TRY-448.43m
- Incorporated2012
- Employees680.00
- LocationTurk Ilac ve Serum Sanayi ASBugduz Mah. Enver Pasa Cad. No:8 AkyurtAnkara 06750TurkeyTUR
- Phone+90 3 128376767
- Fax+90 3 128442106
- Websitehttps://www.turkilac.com.tr
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biome Australia Ltd | 572.14m | 6.64m | 2.93bn | 30.00 | 456.99 | 20.05 | 207.19 | 5.12 | 0.0009 | 0.0009 | 0.0833 | 0.0212 | 1.83 | 2.39 | 5.14 | -- | 2.12 | -43.09 | 5.42 | -74.65 | 61.27 | 60.84 | 1.16 | -31.29 | 1.02 | 1.80 | 0.3966 | -- | 41.43 | 80.32 | 112.85 | -- | 2.18 | -- |
| Shri Ahimsa Naturals Ltd | 557.18m | 128.55m | 3.01bn | -- | 18.17 | 3.68 | 21.87 | 5.40 | 14.65 | 14.65 | 61.23 | 72.37 | 0.7957 | 1.80 | 4.75 | -- | 18.36 | 25.55 | 19.42 | 31.51 | 48.63 | 53.50 | 23.07 | 25.19 | 12.68 | -- | 0.00 | -- | 22.86 | 34.75 | 17.31 | 78.70 | 53.34 | -- |
| Turk Ilac Ve Serum Sanayi AS | 3.47bn | -448.43m | 3.02bn | 680.00 | -- | 1.58 | -- | 0.8723 | -2.77 | -2.77 | 21.46 | 11.81 | 0.7175 | 4.08 | 2.50 | 6,404,979.00 | -9.29 | 3.32 | -15.79 | 5.13 | 28.97 | 25.55 | -12.94 | 2.72 | 0.9144 | 0.6667 | 0.5023 | 0.00 | -7.45 | 75.98 | -52.59 | 39.94 | 42.96 | -- |
| Pliant Therapeutics Inc | 0.00 | -7.66bn | 3.03bn | 171.00 | -- | 0.3467 | -- | -- | -2.87 | -2.87 | 0.00 | 3.26 | 0.00 | -- | -- | 0.00 | -48.60 | -38.70 | -52.81 | -41.26 | -- | -- | -- | -1,044.87 | -- | -- | 0.1319 | -- | -100.00 | -- | -30.35 | -- | 31.90 | -- |
| Scilex Holding Co | 1.76bn | -16.40bn | 3.06bn | 30.00 | -- | -- | -- | 1.74 | -33.18 | -33.18 | 4.08 | -28.88 | 0.2145 | 7.27 | 1.85 | 350,956.50 | -177.73 | -- | -- | -- | 68.59 | 75.06 | -828.56 | -176.54 | 0.0429 | -3.76 | -- | -- | 21.07 | 21.89 | 56.40 | -- | -49.14 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Pardus Portf�y Y�netimi A.Sas of 03 Dec 2025 | 16.51m | 10.20% |
| Dimensional Fund Advisors LPas of 08 Jan 2026 | 284.39k | 0.18% |
| DFA Australia Ltd.as of 30 Nov 2025 | 1.46k | 0.00% |
